Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer by Mounira El Demery et al.
El Demery et al. Clinical and Translational Medicine 2014, 3:31
http://www.clintransmed.com/content/3/1/31RESEARCH Open AccessSerum Matrix Metalloproteinase-7 is an
independent prognostic biomarker in advanced
bladder cancer
Mounira El Demery1, Gaiané Demirdjian-Sarkissian2, Simon Thezenas3, William Jacot4, Yassine Laghzali3,
Bruno Darbouret2, Stéphane Culine5, Xavier Rebillard6 and Pierre-Jean Lamy7*Abstract
Background: Urine markers have been studied extensively but there is a lack of blood prognostic markers in
bladder cancer. MMP-7 is produced by stromal cells and by tumor cells and is overexpressed in a variety of epithelial
and mesenchymal tumors. In this study, we assessed with an immunoassay we developed, the prognostic value of
serum MMP-7 in a series of patients with advanced bladder cancer.
Methods: Serum samples were collected from 56 patients with advanced bladder cancer who were treated at the
Montpellier Cancer Institute between March 2003 and December 2004. MMP-7 was quantified in serum samples by
using a homogeneous sandwich fluoroimmunoassay we developed based on the time resolved amplified cryptate
emission (TRACE) technology.
Results: The median overall survival of the study population was 2.2 years (95% CI, 1.4 to 3.0) with 1- and 5-year survival
rates of 73% (95% CI, 59% to 82%) and 25% (95% CI, 14% to 37%), respectively. High MMP-7 serum levels were
associated with poor survival. Using a cut-off value of 11.5 ng/mL, the median overall survival was 3.0 years
(95% CI, 1.5 to 5.1) for patients with MMP-7 serum level <11.5 ng/mL and 1.3 years (95% CI, 0.8 to 2.5) for
patients with serum level ≥11.5 ng/mL. Multivariate analysis identified high MMP-7 serum concentration as an
independent prognostic factor for survival in patients with advanced bladder cancer (R = 2.1, 95% CI, 1.1 to 4.4).
Conclusions: Our results show that the MMP-7 serum concentration is an independent prognostic factor in patients
with locally advanced and or metastatic bladder cancer.
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Bladder urothelial cell carcinoma (BUCC) is the fourth
most common cancer in men and overall the fifth most
common cancer with 11965 new cases and 4772 BUCC-
related deaths in France in 2012 [1]. At diagnosis, ap-
proximately 75% of bladder cancers are non-muscle
invasive [pTa, pT1, carcinoma in situ (CIS)], 25% are
muscle-invasive (pT2-pT4) and 5% are metastatic (N1-3
or M1) [2]. The standard treatment includes transureth-
ral resection of the bladder tumor (TURBT) and intrave-
sical chemotherapy or immunotherapy for superficial* Correspondence: Pierre-Jean.Lamy@icm.unicancer.fr
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in any medium, provided the original work is ptumors and radical cystectomy for non muscle invasive
tumors. However, 50-70% of patients will experience
tumor recurrence within 5 years. The 5-year survival
rate of patients with non-muscle invasive disease is be-
tween 95% (Ta tumors) and 75% (T1 tumors), and al-
most 25% of patients with a Ta-T1 tumor will eventually
develop invasive disease [3]. The 5-year survival rate fur-
ther decreases in patients with muscle invasive or meta-
static disease (60% and 35% for T2 and T3 tumors,
respectively, and only 10% for T4 tumors) [4]. The blad-
der cancer heterogeneity in terms of clinical behavior
means that prognostic tools based on clinical and patho-
logical variables are not accurate enough to reliablyis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ment choices. Urine markers have been studied exten-
sively but cannot be easily standardized due to
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MMP7 (ng/mL)
Mean (s.d.) 10.6 (8.8)
Median (range) 8.5 (2.8-44.2)
<3.6 1.0 -
[3.6 – 4.2] 0.4 (0.1-0.2) 0.296
[4.2 – 5.2] 2.9 (0.7-12.1) 0.126
[5.2 – 7.2] 1.5 (0.4-5.8) 0.493
[7.2 – 8.4] 4.8 (1.2-19.5) 0.026
[8.4 – 9.6] 1.2 (0.3-5.7) 0.789
[9.6 – 11.5] 0.7 (0.2-3.0) 0.682
[11.5 – 13.4] 5.4 (1.3-23.6) 0.022
[13.4 – 17.5] 3.4 (0.9-13.1) 0.072
≥ 17.5 3.7 (0.9-15.5) 0.067
The MMP7≥11.5 ng/mL categories showed consecutive P<0.1 values.bladder cancer are lacking. New markers to aid in the
diagnosis and prognosis as well as to identify the op-
timal treatment and monitor tumor progression are
therefore needed [5].
Matrix Metalloproteinases (MMPs) are a family of
zinc-dependent proteolytic enzymes that cleave extracel-
lular matrix proteins (ECMs). ECM degradation is an
important step in both physiological (embryonic devel-
opment, reproduction, wound healing) and pathologicalTable 3 Univariate survival analyses
Variable HR [95%CI] P
Gender
Male 1.0
Female 0.75 [0.34 ; 0.63] 0.472
pN
pN0 1.0
pN+ 2.33 [0.87 ; 6.24] 0.090
pM pM
M0 1.0
M1 1.64 [0.74 ; 3.62] 0.225
Grade
2 1.0
3 0.95 [0.13 ; 7.00] 0.96
Hemoglobin
Normal 1.0
Abnormal 1.39 [0.76 ; 2.56] 0.29
PS
0-1 1.0
2-4 1.31 [0.58 ; 2.98] 0.51
MMP-7
<11.5 ng/mL 1.0
>=11.5 ng/mL 2.55 [1.33 ; 4.90] 0.005
Table 4 Multivariate survival analysis
HR (CI 95%) P
Gender Male 1.0
Female 0.7 (0.3-1.6) 0.421
OMS 0/1 1.0
2/3/4 1.1 (0.5-2.8) 0.788
MMP-7 <11.5 ng/mL 1.0
≥11.5 ng/mL 2.1 (1.1- 4.4) 0.035
Hemoglobin Normal 1.0
Abnormal 1.4 (0.7-2.6) 0.337
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formation) [6]. Furthermore, MMPs can influence sev-
eral molecular processes involved in tumor progression
through their ability to cleave pro-apoptotic factors, cell
surface molecules, cell adhesion molecules and growth
factors [7,8]. MMPs can mobilize pro-angiogenic inhibi-
tors, such as endostatin and angiostatin [9,10]. MMP-7,
also known as matrilysin, is the smallest MMPs; its
molecular weight as a proenzyme is 28 KDa and it de-
creases to 19 KDa after activation induced by plasmin
and trypsin [11]. MMP-7 is expressed in the ductal and
glandular epithelia of normal mammary and parotid
glands, liver, pancreas and prostate. In human tumors,
MMP-7 is produced by stromal cells (macrophages, fi-
broblasts and endothelial cells) and also by tumor cells
[6]. MMP-7 is overexpressed in a variety of epithelial
and mesenchymal tumors, such as esophageal, colon,
liver, renal and pancreatic cancer [12-14]. Furthermore,
increased circulating levels of MMP-7 have been corre-
lated with metastatic disease and poor patients’ survival
in colorectal, ovarian and renal cancer [15-18]. ElevatedFigure 1 Overall survival probability function according to serum MMMMP-7 concentration was detected in urine samples
from patients with regional or distant metastasis in com-
parison to patients with localized disease and controls,
suggesting that MMP-7 could be a putative biomarker
for the diagnosis and monitoring of bladder cancer [19].
Moreover, MMP-7 plasma levels are significantly higher
in patients with bladder cancer at high risk of diseases
progression [20]. Similarly, analysis of MMP-7 plasma
level in 135 patients with localized bladder cancer (≥T1)
confirmed the significant association of MMP-7 level
with cancer-related death [21].
In the present study, we measured MMP-7 serum
levels particularly in patients with advanced bladder can-
cer and analyzed their correlation with clinical parame-
ters to determine whether serum MMP-7 could also be
used as a prognostic marker.Methods
Clinical samples
Serum samples from 56 patients with bladder cancer were
collected in the Department of Medical Oncology at the
Institut du Cancer de Montpellier (ICM) between March
2003 and December 2004 and stored in a certified
AFNOR 96900 biobank (ICM biobank number: BB-0033-
00059). The patients’ medical records were used to ex-
tract information on the clinico-pathological features, last
follow-up and cause of death. This study was performed
in compliance with the relevant French ethical standards
and was validated by our Institutional Research Ethics
Board (CORT). According to our biobank policy all pa-
tients gave their general consent for the use of their bio-
logical samples in research.P-7 level in bladder cancer.
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We previously developed and validated a homogeneous
sandwich fluoroimmunoassay [18] based on the TRACE
technology. The specific MMP-7 immunoassay was set
up using two monoclonal anti-human MMP-7 anti-
bodies (29S and 01S) generated by immunization of fe-
male BALB/c mice with human MMP-7 recombinant
protein (R&D Systems Europe Ltd., Abingdon, UK). The
immunoassay was performed by incubating 50 μL of
each patient’s serum sample or calibrator with 50 μL of
AF647-conjugated 29S-antibody solution) and 50 μL of )
cryptate-conjugated 01S-antibody solution at 37°C in a
BRAHMS KRYPTOR automate (Thermo Fisher Scien-
tific, Hennigsdorf, Germany), according to the manu-
facturer’s instructions and as previously described [18].
Results were given in μg/L. Standards ranged from 0.5 to
40 μg/L.
Statistical analysis
Categorical variables were reported using contingency
tables. For continuous variables, median and range were
computed. To investigate their associations with the
clinical, pathological and biological parameters, univariate
statistical analyses were performed using the Pearson’s
chi-square test or the Fisher’s exact test, when applicable,
for categorical variables, and using the Kruskal-Wallis test
or the Student’s t test for continuous variables. Survival
times were measured from the date of the diagnosis of
bladder cancer to the event date (or to the last available
follow-up, if not applicable). Overall survival rates (with
event defined as death from any cause) were estimated
according to the Kaplan-Meier method and presented
with 95% confidence intervals (CIs). Patients alive were
censored at the date of the last follow-up. The median
follow-up was estimated according to the « reverse
Kaplan-Meier method » and presented with 95% CIs.
Survival curves were drawn and the log-rank test was
performed to assess differences between groups. Multi-
variate analyses were carried out using Cox propor-
tional hazards regressions with a stepwise selection
procedure to investigate known prognostic factors.
Hazards Ratios (HR) with 95% CIs show the risk of ex-
periencing the event (death from any cause) during the
follow-up period. All reported P values are two-sided
and the significance level was set at 5% (p < 0.05). Stat-
istical analyses were performed using the STATA 11
software (Stata Corporation, College Station, TX).
Results
Clinical background
Patient’s characteristics at time of diagnosis are shown
in Table 1. A total of 56 patients who received a diag-
nosis of urothelial tumor between January 1995 and
November 2004 were enrolled in this study. At thetime of the analysis, 35/56 patients (62.5%) had meta-
static disease and 20 patients (35.7%) had localized dis-
ease. Seven patients (12.5%) had a Performance Status
(PS) of 2/3. Forty-six (82.1%;) had grade 3 tumor at
diagnosis. Surgery was performed for 18 (32.1%) pa-
tients; radical cystectomy for 13 (23.2%) patients and
nephrectomy for 5 (8.9%) patients. Seventeen patients
(30.4%) received post-operative chemotherapy and 12
(21.4%) concomitant radio-chemotherapy. The median
follow-up was 8.1 years (range: 0.2- 16.2 years).
MMP-7 serum concentration and survival:
The median overall survival of the study population was
2.2 years (95% CI 1.4- 3.0) with 1- and 5-year survival
rates of 73% (95% CI 59-82%) and 25% (95% CI 14-37%),
respectively. Among the 56 patients, 47 died (38 pa-
tients: cancer-related death; 9 patients: non-cancer re-
lated death). MMP-7 serum levels were categorized in
deciles and then the effect of MMP-7 serum level on the
survival time was assessed (univariate Cox regression
analysis). MMP-7 serum levels higher than 11.5 ng/mL
were significantly associated with poor prognosis
(Table 2). Therefore, 11.5 ng/mL was used as cut-off to
classify patients as low (<11.5 ng/mL serum MMP-7)
and high risk (≥11.5 ng/mL serum MMP-7) for the uni-
variate (Table 3) and multivariate analysis (Table 4). The
median overall survival of patients with MMP-7 serum
level <11.5 ng/mL and those with serum level ≥11.5 ng/mL
was 3.0 years (95% CI 1.5-5.1) and 1.3 years (95%
CI 0.8-2.5), respectively (Figure 1); p(log rank) = 0.004
(Table 1). Multivariate analysis indicated that MMP-7
serum level ≥11.5 ng/mL was an independent predictor
of poor survival (Table 4).
Discussion
The prognosis of advanced bladder cancer is generally
poor [22]. Therefore, new therapeutic strategies are
needed to improve the outcome of patients with locally
advanced or metastatic cancer. In this setting, the know-
ledge of prognostic determinants might be important for
treatment planning and for patients’ inclusion in clinical
trials.
MMP-7 is overexpressed in many cancers. Previous
studies have reported elevated MMP-7 concentration in
urine samples and also in plasma samples from patients
with bladder cancer. In urine samples no significant dif-
ference was detected in MMP-7 levels between bladder
cancer patients and controls, suggesting that only MMP-
7 plasma levels could be a putative biomarker for the
diagnosis of bladder cancer [19-21]. Moreover, MMP-7
plasma levels may be used to identify patients at high
risk of diseases progression [20,21].
The aim of this study was to analyze the prognostic value
of MMP-7 serum level particularly in advanced bladder
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wich fluoroimmunoassay) in serum samples from 56 pa-
tients with locally advanced or metastatic disease at time of
MMP-7 analysis. Survival analysis made after categorization
of MMP-7 serum levels into deciles indicated that con-
centrations higher than 11.5 ng/mL were associated
with higher risk of poor prognosis (P < 0.07). Multivari-
ate analyses carried out using this cut-off and Cox pro-
portional hazards regressions with a stepwise selection
procedure to investigate the association with known
prognostic factors showed that MMP-7 serum level is a
strong independent prognostic factor of overall survival
(HR = 2.1, 95% CI 1.1-4.5, p = 0.035). Our findings are
consistent with those reported by Szarvas et al who ana-
lyzed MMP-7 gene expression and serum level in 179 pa-
tients with urothelial bladder cancer (160 patients with
BUCC and 19 controls). The study showed that MMP-7
was significantly higher in both tumor and serum samples
from patients with metastatic BUCC than in those without
known metastasis. Furthermore, both high tissue and
serum levels were stage- and grade-independent risk fac-
tors for metastasis and cancer-related death [23].
Although, the power of our analysis was reduced due
to the small number of patients, our results suggest that
MMP-7 serum level may be a prognostic factor for pa-
tients with locally advanced and or metastatic bladder
cancer. We defined a MMP-7 cut-off value (11.5 ng/mL)
that clearly differentiates two groups of patients: the
overall survival of patients with low MMP-7 serum level
was 3 years versus only 1.3 year for patients with high
MMP-7 serum level.
Conclusions
Our results show that the MMP-7 serum concentration
is an independent prognostic factor in patients with lo-
cally advanced and or metastatic bladder cancer. Further
studies are needed to determine how MMP-7 can ad-
equately assign patients to prognostic subgroups for dif-
ferent treatments and how it can be used in the design
of clinical trials.
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